North America Long-Term Injectable Drug Delivery Market Size and Forecast (2021

Description

List of Tables

The North America Long-Term Injectable Drug Delivery Market is projected to expand from US$ 2,893.2 Million in 2025 to US$ 6,168.8 Million by 2034. The market is expected to register a CAGR of 8.8% during the forecast period from 2026 to 2034.

Executive Summary and North America Long-Term Injectable Drug Delivery Market Analysis:

The North America Long-Term Injectable Drug Delivery Market, covering the United States, Canada, and Mexico, is experiencing steady expansion as healthcare systems increasingly emphasize sustained and convenient treatment options. The rising incidence of chronic conditions, including diabetes, cancer, cardiovascular diseases, and other long-term disorders, is creating a greater need for therapies capable of maintaining therapeutic drug levels over extended periods. Long-acting injectable formulations can reduce the frequency of administration, helping patients follow prescribed treatment schedules and potentially improving adherence.

The aging population across North America is another important contributor to market development. Older patients frequently manage multiple medications and may benefit from treatment approaches that reduce the burden associated with frequent dosing. At the same time, advances in pharmaceutical formulation and delivery technologies are improving the performance of long-term injectable systems. Innovations involving biodegradable polymers, depot formulations, controlled-release mechanisms, and advanced injection devices are helping extend drug release while supporting safety and effectiveness.

The region's established healthcare infrastructure, high healthcare expenditure, and strong pharmaceutical and biotechnology industries provide a favorable environment for commercialization. Regulatory support and continued research investment are also encouraging the development of new long-acting therapies. Furthermore, increasing acceptance of self-injection and home-based healthcare is making injectable treatments more convenient for patients outside traditional clinical settings.

The continued growth of biologics, specialty medicines, and complex therapies is providing another source of demand because many of these products require specialized delivery technologies. As pharmaceutical companies seek to improve treatment convenience and patient outcomes, long-term injectable systems are becoming increasingly important across several therapeutic areas.

Strategic Insights

North America Long-Term Injectable Drug Delivery Market Segmentation Analysis:

By Formulation Packaging (Ready-to-Use), the North America Long-Term Injectable Drug Delivery Market is segmented into Ampoules, Vials, Cartridges, and Bottles. The Vials segment held the largest market share in 2025.

By Therapeutic Application, the market is divided into Diabetes, Oncology, Auto-Immune Disorders, Cardiovascular Diseases, Infectious Diseases, Pain Management, and Others. Diabetes represented the dominant segment in 2025.

By Route of Administration, the market is categorized into Subcutaneous, Intramuscular, Intravenous, and Others. The Subcutaneous segment accounted for the largest share in 2025.

By Usability, the market comprises Disposable Injectors and Re-usable Injectors. Disposable Injectors led the market in 2025.

By End User, the market is segmented into Pharmaceutical and Biopharma Companies and CMOs and CDMOs. Pharmaceutical and Biopharma Companies represented the leading segment in 2025.

Market Report Scope

North America Long-Term Injectable Drug Delivery Market Outlook

The growing prevalence of chronic noncommunicable diseases and psychiatric conditions is creating sustained demand for therapies that can provide consistent drug exposure over prolonged periods. Cardiovascular diseases, cancer, chronic respiratory disorders, and diabetes are among the major conditions requiring long-term disease management. According to the World Health Organization (WHO), noncommunicable diseases accounted for approximately 43 million deaths globally in 2021, equivalent to around 75% of deaths unrelated to pandemics. Diabetes has also become increasingly prevalent, with the WHO reporting that the number of adults living with the condition increased from approximately 200 million in 1990 to 830 million in 2022.

The burden is particularly significant in the United States. The Centers for Disease Control and Prevention (CDC) estimates that about 60% of US adults have at least one chronic health condition, while a substantial proportion manage multiple conditions simultaneously. Mental health disorders add another layer of treatment complexity. The National Institute of Mental Health (NIMH) reported that 23.1% of US adults, equivalent to approximately 59.3 million people in 2022, experienced mental illness. Conditions such as schizophrenia and bipolar disorder commonly require long-term pharmacological management to maintain stability and reduce the likelihood of relapse.

Long-term injectable delivery systems can address these treatment requirements by releasing medications gradually over weeks or months. Long-acting antipsychotics, including paliperidone palmitate, can support treatment continuity in schizophrenia and bipolar disorder. Similarly, long-acting HIV therapies such as cabotegravir and rilpivirine can reduce dependence on daily oral medication. Depot formulations of leuprolide acetate are also used in conditions including prostate cancer and endometriosis, with dosing schedules extending from monthly administration to intervals of several months.

As chronic disease prevalence rises and healthcare providers seek more convenient approaches to long-term treatment, extended-release injectable therapies offer an alternative to frequent dosing. By reducing administration frequency and supporting consistent drug exposure, these technologies can help minimize missed doses, improve treatment continuity, and reduce the burden associated with daily medication routines.

North America Long-Term Injectable Drug Delivery Market Country Insights

By country, the North America Long-Term Injectable Drug Delivery Market is segmented into the United States, Canada, and Mexico. The United States held the largest market share in 2025.

The US is the region's largest market due to its substantial patient population, advanced healthcare infrastructure, high pharmaceutical expenditure, and strong presence of drug developers and medical technology companies. Chronic diseases such as diabetes, HIV, and psychiatric disorders generate considerable demand for long-duration therapies that can improve treatment adherence and simplify medication schedules.

According to the CDC's National Diabetes Statistics Report released in January 2026, approximately 40.1 million people, representing 12% of the US population, were estimated to have diabetes in 2023. Long-acting injectable technologies can help address treatment challenges by reducing administration frequency and maintaining more consistent therapeutic exposure. Long-acting antiretroviral therapies are similarly being used to support HIV treatment and prevention, while extended-release antipsychotics can help patients maintain continuity of treatment for schizophrenia and bipolar disorder.

Recent developments demonstrate continued innovation in this area. In February 2026, the US Food and Drug Administration accepted a New Drug Application for olanzapine extended-release injectable suspension (TEV-749), a once-monthly subcutaneous formulation being developed for adults with schizophrenia. In 2025, the FDA also approved lenacapavir as a six-monthly subcutaneous HIV pre-exposure prophylaxis option for eligible individuals, representing an important advancement in reducing dosing frequency for HIV prevention.

These developments highlight the industry's continued focus on extending drug-release intervals, simplifying treatment schedules, and improving patient convenience. Ongoing innovation in injectable formulations and delivery devices is expected to support the US market's continued leadership.

North America Long-Term Injectable Drug Delivery Market Company Profiles

Key companies operating in the North America Long-Term Injectable Drug Delivery Market include Terumo Corp, Phillips-Medisize, Gerresheimer AG, West Pharmaceutical Services Inc, Ypsomed Holding AG, Schott AG, AptarGroup Inc, Becton Dickinson and Co, Owen Mumford Ltd, and SHL Medical.

These companies are pursuing strategies such as geographic expansion, product innovation, strategic collaborations, capacity enhancement, and mergers and acquisitions. Through these initiatives, market participants are seeking to strengthen their delivery-device portfolios, develop more patient-friendly solutions, expand manufacturing capabilities, and capture opportunities created by the growing adoption of long-acting injectable therapies.

Product Code: TIPRE00044020

1. Executive Summary

1.1 Analyst Market Outlook

2. Global Long-Term Injectable Drug Delivery Market Landscape

2.1 Overview
2.2 Value Chain Analysis
2.3 Supply Chain Analysis
- 2.3.1 List of Manufacturers/Suppliers
- 2.3.2 List of Potential Customers (Upto 50)
2.4 Porter's Five Forces Analysis
2.5 PEST Analysis

3. Competitive Landscape

3.1 Company Benchmarking by Key Players
3.2 Market Share Analysis, 2025 - By Key Players
3.3 Market Concentration

4. North America Long-Term Injectable Drug Delivery Market - Key Industry Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Future Trends
4.5 Impact of Drivers and Restraints:

5. Long-Term Injectable Drug Delivery Market - North America Analysis

5.1 North America Long-Term Injectable Drug Delivery Market Revenue (US$ Million), 2021 - 2034
5.2 North America Long-Term Injectable Drug Delivery Market Revenue Forecast and Analysis

6. North America Long-Term Injectable Drug Delivery Market Revenue Analysis - by Formulation Packaging (ready-to-use)

6.1 North America Long-Term Injectable Drug Delivery Market Forecast and Analysis by Formulation Packaging (ready-to-use)
- 6.1.1 Ampoules
  - 6.1.1.1 Overview
  - 6.1.1.2 Ampoules: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.2 Vials
  - 6.1.2.1 Overview
  - 6.1.2.2 Vials: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.3 Cartridges
  - 6.1.3.1 Overview
  - 6.1.3.2 Cartridges: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.4 Bottles
  - 6.1.4.1 Overview
  - 6.1.4.2 Bottles: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

7. North America Long-Term Injectable Drug Delivery Market Revenue Analysis - by Therapeutic Application

7.1 North America Long-Term Injectable Drug Delivery Market Forecast and Analysis by Therapeutic Application
- 7.1.1 Diabetes
  - 7.1.1.1 Overview
  - 7.1.1.2 Diabetes: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.2 Oncology
  - 7.1.2.1 Overview
  - 7.1.2.2 Oncology: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.3 Auto-Immune Disorders
  - 7.1.3.1 Overview
  - 7.1.3.2 Auto-Immune Disorders: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.4 Cardiovascular Diseases
  - 7.1.4.1 Overview
  - 7.1.4.2 Cardiovascular Diseases: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.5 Infectious Diseases
  - 7.1.5.1 Overview
  - 7.1.5.2 Infectious Diseases: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.6 Pain Management
  - 7.1.6.1 Overview
  - 7.1.6.2 Pain Management: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.7 Others
  - 7.1.7.1 Overview
  - 7.1.7.2 Others: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

8. North America Long-Term Injectable Drug Delivery Market Revenue Analysis - by Route Of Administration

8.1 North America Long-Term Injectable Drug Delivery Market Forecast and Analysis by Route Of Administration
- 8.1.1 Subcutaneous
  - 8.1.1.1 Overview
  - 8.1.1.2 Subcutaneous: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.2 Intramuscular
  - 8.1.2.1 Overview
  - 8.1.2.2 Intramuscular: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.3 Intravenous
  - 8.1.3.1 Overview
  - 8.1.3.2 Intravenous: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.4 Others
  - 8.1.4.1 Overview
  - 8.1.4.2 Others: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

9. North America Long-Term Injectable Drug Delivery Market Revenue Analysis - by Usability

9.1 North America Long-Term Injectable Drug Delivery Market Forecast and Analysis by Usability
- 9.1.1 Disposable Injectors
  - 9.1.1.1 Overview
  - 9.1.1.2 Disposable Injectors: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 9.1.2 Re-usable Injectors
  - 9.1.2.1 Overview
  - 9.1.2.2 Re-usable Injectors: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

10. North America Long-Term Injectable Drug Delivery Market Revenue Analysis - by End User

10.1 North America Long-Term Injectable Drug Delivery Market Forecast and Analysis by End User
- 10.1.1 Pharmaceutical and Biopharma Companies
  - 10.1.1.1 Overview
  - 10.1.1.2 Pharmaceutical and Biopharma Companies: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 10.1.2 CMOs and CDMOs
  - 10.1.2.1 Overview
  - 10.1.2.2 CMOs and CDMOs: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

11. North America Long-Term Injectable Drug Delivery Market - Country Analysis

11.1 North America
- 11.1.1 North America Long-Term Injectable Drug Delivery Market Forecast and Analysis - by Country
  - 11.1.1.1 United States Market
    - 11.1.1.1.1 United States: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.1.2 United States: North America Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.1.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.1.2.2 Therapeutic Application
      - 11.1.1.1.2.3 Route Of Administration
      - 11.1.1.1.2.4 Usability
      - 11.1.1.1.2.5 End User
  - 11.1.1.2 Canada Market
    - 11.1.1.2.1 Canada: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.2.2 Canada: North America Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.2.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.2.2.2 Therapeutic Application
      - 11.1.1.2.2.3 Route Of Administration
      - 11.1.1.2.2.4 Usability
      - 11.1.1.2.2.5 End User
  - 11.1.1.3 Mexico Market
    - 11.1.1.3.1 Mexico: North America Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.3.2 Mexico: North America Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.3.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.3.2.2 Therapeutic Application
      - 11.1.1.3.2.3 Route Of Administration
      - 11.1.1.3.2.4 Usability
      - 11.1.1.3.2.5 End User

12 Long-Term Injectable Drug Delivery Market Industry Landscape

13 - Key Company Profiles

13.1 Terumo Corp
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Phillips-Medisize
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Gerresheimer AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 West Pharmaceutical Services Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Ypsomed Holding AG
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Schott AG
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 AptarGroup Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Becton Dickinson and Co
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Owen Mumford Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 SHL Medical
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 Glossary
14.2 Research Methodology and Approach
- 14.2.1 Secondary Research
- 14.2.2 Primary Research
- 14.2.3 Market Estimation Approach
  - 14.2.3.1 Supply Side Analysis
  - 14.2.3.2 Demand Side Analysis
- 14.2.4 Research Assumptions and Limitations
- 14.2.5 Currency Conversion
14.3 About The Insight Partners
14.4 Market Intelligence Cloud